DIA 48th Annual Meeting
Click here to go to the previous page
Microdosing: Past Experience and Future Role in Translational Medicine
Track
:
Track 04: Nonclinical and Translational Development/Early Phase Clinical Development
Program Code:
353
Date:
Wednesday, June 27, 2012
Time:
1:30 PM to 3:00 PM
EST
CHAIR
:
Tal Burt, Duke Clinical Research Institute, United States
PRESENTER
(S):
Graham Lappin, Xceleron Ltd., United Kingdom Joseph Bertino, Bertino Consulting, United States
Martin Bauer, Medical University of Vienna, Austria
Description
Microdosing holds the promise of increasing drug selection efficiency through the introduction of subpharmacological doses of test articles to humans. The session examines existing data, potential applications and future role of microdosing.
Learning Objectives:
Interpret pharmacokinetic (PK) and pharmacodynamic (PD) data from microdosing studies and appraise their relevance to pharmacological dose PK and PD estimates
Describe microdosing applications and their potential role in translational clinical research.
Learning Objectives:
Interpret pharmacokinetic (PK) and pharmacodynamic (PD) data from microdosing studies and appraise their relevance to pharmacological dose PK and PD estimates
Describe microdosing applications and their potential role in translational clinical research.
This session is a part of:
Handout Online
